Loibl S, et al. - In the BrighTNess trial, it was demonstrated that the proportion of triple-negative breast cancer patients who achieved a pathologic complete response was improved as a result of adding veliparib and carboplatin to paclitaxel followed by doxorubicin and cyclophosphamide. No improvement was noted with the addition of veliparib to carboplatin and paclitaxel. Manageable, but increased toxicities were reported with the addition of carboplatin (with or without veliparib) to paclitaxel. These toxicities did not substantially impact treatment delivery of paclitaxel followed by doxorubicin and cyclophosphamide. Overall, the addition of carboplatin appeared to have a favourable risk to benefit profile and might be considered as a potential component of neoadjuvant chemotherapy for patients with high-risk, triple-negative breast cancer.